MURRYSVILLE, Pa., April 11 /PRNewswire-FirstCall/ -- RESPIRONICS, INC. today announced that David P. White, M.D., has been named Chief Medical Officer (CMO) of Respironics. Dr. White will be responsible for leading the Company’s clinical research strategies and programs in the sleep and respiratory markets. His appointment becomes effective on May 1, 2006.
“We are pleased to have a physician and leading researcher of David White’s stature join our management team,” said John L. Miclot, President and Chief Executive Officer. “I am confident that David’s clinical expertise and extensive research background in sleep disorders will be a tremendous asset to our organization. Increasing the breadth and scope of our clinical research capabilities is a key element of our strategy, which calls for continued expansion of our presence in the sleep and respiratory markets.”
Dr. White currently serves as Director of the Clinical Sleep Disorders Program at Brigham and Women’s Hospital and as Professor of Sleep Medicine at Harvard Medical School in Boston, Massachusetts. Earlier in his career, Dr. White served on the faculty at Penn State University Medical Center in Hershey, Pennsylvania and the University of Colorado Health Science Center. Dr. White is a widely published researcher and is a frequent lecturer on the monitoring, diagnosing and treatment of sleep disorders.
Dr. White is board-certified in sleep disorders medicine, internal medicine, pulmonary disease, and critical care medicine. He earned a B.S. degree from Washington and Lee University and obtained his medical school training at Emory University. He has held numerous leadership roles with the professional societies associated with sleep and pulmonary medicine. His national activities include past-president of the American Academy of Sleep Medicine, Chair of the Advisory Board of the National Center on Sleep Disorders Research (NIH) and Chair of the Task Force to write the latest NIH Research Plan in the area of sleep and its disorders. He has also served on the Pulmonary Subspecialty Board for the American Board on Internal Medicine. He is also currently the Editor-in-Chief of the Journal SLEEP, is a regular member of the Respiratory Integrative Biology and Translational Research Study Section at the NIH, and is the Chair of the Test Writing Committee for the first American Board of Medical Specialties Board Exam in Sleep Medicine.
Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,500 associates worldwide. Further information can be found on the Company’s Web site: http://www.respironics.com.
This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company’s marketing, sales, and promotion programs; future sales and acceptance of the Company’s products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; acquisition integration; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; and third party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company’s financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.
Respironics, Inc.
CONTACT: Dan Bevevino, Chief Financial Officer of Respironics, Inc.,+1-724-387-5235; or General: Joe Calabrese, +1-212-827-3772, or Investors:Julie Tu, +1-212-827-3776, both of Financial Relations Board
Web site: http://www.respironics.com/
